Castleark Management’s PTC Therapeutics PTCT Stock Holding History

Castleark Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77M	Sell	33,900 -57,980	-63%	-$4.19M	0.07%	188
2026 Q1	$6.26M	Sell	91,880 -4,980	-5%	-$353K	0.21%	120
2025 Q4	$7.36M	Buy	+96,860	New	+$7.04M	0.22%	112
2019 Q2	–	Sell	-94,102	Closed	-$3.54M	–	385
2019 Q1	$3.54M	Sell	94,102 -1,593	-2%	-$53.5K	0.13%	180
2018 Q4	$3.28M	Sell	95,695 -74,225	-44%	-$2.67M	0.14%	182
2018 Q3	$7.99M	Buy	+169,920	New	+$7.03M	0.23%	139

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Castleark Management's PTCT Position: Q2 2026 in Review

Castleark Management reduced its PTC Therapeutics (PTCT) stake by 63% in Q2 2026, selling an estimated $4.19M and leaving 33,900 shares worth $2.77M. The position accounts for 0.07% of the portfolio, ranked #188.

Castleark Management first reported a position in PTCT in Q3 2018 and has held it in 6 quarters since. The position peaked at $7.99M in Q3 2018. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Castleark Management held 33,900 shares of PTC Therapeutics worth $2.77M as of Q2 2026.
Castleark Management sold 57,980 PTC Therapeutics shares in Q2 2026, an estimated $4.19M.
PTC Therapeutics made up 0.07% of Castleark Management's portfolio in Q2 2026, its #188 holding.
Castleark Management first reported a position in PTC Therapeutics in Q3 2018 and has held it in 6 quarters since.
Castleark Management's PTC Therapeutics position peaked at $7.99M in Q3 2018.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.